StockData
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31

Tilray Brands, Inc.

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$3.03−0.01 (-0.33%)

Close on Oct 19, 2026

Market cap
$404.02M
P/E (TTM)
–
Dividend yield
–

About Tilray Brands

Medicinal Chemicals & Botanical Products, SIC 2833

Tilray Brands, Inc. is a consumer goods company operating in four segments: Beverage, Cannabis, Distribution, and Wellness. In beverage, it produces, markets, and sells craft beers, craft spirits, ready-to-drink beverages, ciders, and non-alcoholic drinks. Its cannabis segment cultivates, processes, and sells adult-use and medicinal cannabis products, including dried flower, pre-rolls, vapes, and edibles. Through its distribution and wellness businesses, the company distributes pharmaceutical products and manufactures hemp-based foods. Tilray supplies retail consumers, medical patients, doctors, hospitals, pharmacies, and commercial wholesalers.

Headquartered in Leamington and New York, the company operates in Canada, the United States, Europe, Australia, and Latin America. Tilray supplies medical cannabis to patients across more than twenty countries on five continents, with production facilities in Canada, Germany, and Portugal. Its beverage assets include seven production facilities, eighteen brewpubs, and a distillery in the United States, a brewery in Scotland, and thirty-five owned or franchised pubs across the United Kingdom, Ireland, and Australia.

Summary of the business section of Tilray Brands's latest annual report, written by StockData.

Company profile

Company

Legal name
Tilray Brands, Inc.
Founded
2018
Headquarters
New York, NY
Address
445 Park Avenue 10022
Phone
(519) 322-8800
Employees
3,595, May 31, 2026
Industry
Medicinal Chemicals & Botanical Products
Fiscal year ends
May 31
Auditor
PricewaterhouseCoopers LLP, Toronto, Canada

Stock & identifiers

Ticker
TLRY
Exchange
Nasdaq
IPO date
Jul 19, 2018
Shares outstanding
136M, Jul 24, 2026
Public float
$900.00M, Nov 28, 2025
Filer category
Large accelerated filer
Stock splits
1-for-10 reverse, Jan 8, 2026; 1-for-10 reverse, Dec 2, 2025
SEC CIK
1731348
CUSIP
88688T209
ISIN
US88688T2096
LEI
549300Y4V60733TO1478
EIN
82-4310622

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Irwin D. SimonPresident and CEO, Director1,309,031
Mitchell GendelGlobal General Counsel148,644
Denise M. FaltischekChief Strategy Officer199,489
Carl A. MertonChief Financial Officer241,556
Johann Michael HerhaltDirector195,561
Thomas P. LooneyDirector397,520
Renah PersofskyDirector155,357
Steven Michael CohenDirector55,542
David F. ClanachanDirector192,511
David G. HopkinsonDirector43,104

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026
Mr.Simon
$22.16M$18.59M$3.43M$3$16
FY2025
Brendan Kennedy
$0$0$1.99M$3$14
FY2025
Irwin Simon
$10.30M-$5.09M$1.99M$3$14
FY2025
Mr.Simon
$10.30M-$5.09M$1.99M$3$14
FY2024
Brendan Kennedy
$0$0$2.06M$11$21
FY2024
Irwin Simon
$10.14M$11.15M$2.06M$11$21

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of May 31, 2026, we have approximately 3,595 employees worldwide.”

Corporate history

Events identified from SEC filings